Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Sub-category: Pediatric Solid Tumors

Category: Pediatric Oncology

Meeting: 2011 ASCO Annual Meeting

Session Type and Session Title: Oral Abstract Session, Pediatric Oncology I

Abstract No: 9510

Citation: J Clin Oncol 29: 2011 (suppl; abstr 9510)

Author(s): A. S. Pappo, G. T. Armstrong, W. Liu, D. K. Srivastava, W. Leisenring, S. Hammond, M. Stovall, J. P. Neglia, L. L. Robison; St. Jude Children’s Research Hospital, Memphis, TN; Fred Hutchinson Cancer Research Center, Seattle, WA; Nationwide Children's Hospital, Columbus, OH; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Minnesota, Minneapolis, MN

Abstract Disclosures

Abstract:

**Background:** Survivors of childhood cancer are at increased risk of developing subsequent neoplasms. The incidence and clinical characteristics of subsequent melanoma has not been well described in survivors of childhood cancer. **Methods:** Analysis included 14,358 5-year survivors of childhood cancer diagnosed between 1970-1986. Cumulative incidence (CIN) of first occurrence of subsequent melanoma (invasive, ocular, or in situ) was estimated. The association of potential risk factors and CIN of melanoma were tested using cause specific hazards models with age as the time scale and censoring at time of death. Risks for subsequent malignant melanoma as compared to SEER data base (excluding in situ and ocular melanomas) were calculated using standardized incidence ratios (SIR) and excess absolute risk (EAR) per 1000 person years. **Results:** 55 survivors reported 61 malignant melanomas (invasive 50, in situ 9, and ocular 2). Median time to tumor development was 20.7 yrs (range 5.6-35.4yrs). Median age at diagnosis of first subsequent melanoma was 32yrs (10.9 – 49.0 yrs) and 28 were male. Initial diagnoses included leukemia (16), lymphoma (15), soft tissue and bone sarcoma (n=15), brain tumor (5), Wilms’ tumor (3), and neuroblastoma (1). At last contact, 82% of patients were alive. The CIN of first subsequent melanoma (excluding in-situ and ocular) at 36 yrs from initial cancer was 0.72% (95% CI 0.37-1.07). CIN point estimates by diagnosis ranged from 0.23% for brain tumors to 1.3% for soft tissue and bone sarcoma survivors. The SIR was 2.95 (95% CI 2.19 – 3.89), and EAR was 0.12 (95% CI 0.07 – 0.18) per 1000 person years. Occurrence of melanoma was not associated with age at primary cancer diagnosis, sex, race or family history of cancer. **Conclusions:** Although the incidence is low, survivors of childhood cancer are at increased risk for developing malignant melanoma. Continued surveillance and awareness of this risk is critical for early detection and treatment of this disease.

**Associated Presentation(s):**

1. Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.
   
   Meeting: 2011 ASCO Annual Meeting
   
   Presenter: Alberto S. Pappo
   
   Session: Pediatric Oncology I (Oral Abstract Session)

**Other Abstracts in this Sub-Category:**
1. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.

Meeting: 2011 ASCO Annual Meeting   Abstract No: 2   First Author: R. L. Ladenstein
Category: Pediatric Oncology - Pediatric Solid Tumors

2. Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors.

Meeting: 2011 ASCO Annual Meeting   Abstract No: 9500   First Author: V. M. Santana
Category: Pediatric Oncology - Pediatric Solid Tumors


Meeting: 2011 ASCO Annual Meeting   Abstract No: 9501   First Author: J. L. Glade Bender
Category: Pediatric Oncology - Pediatric Solid Tumors

More...

**Abstracts by A. S. Pappo:**

1. Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Meeting: 2011 ASCO Annual Meeting   Abstract No: 9510   First Author: A. S. Pappo
Category: Pediatric Oncology - Pediatric Solid Tumors

2. Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG).

Meeting: 2011 ASCO Annual Meeting   Abstract No: 9516   First Author: D. Walterhouse
Category: Pediatric Oncology - Pediatric Solid Tumors

3. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

Meeting: 2010 ASCO Annual Meeting   Abstract No: 10000   First Author: A. S. Pappo
Category: Sarcoma - Ewing's Sarcoma

More...

**Presentations by A. S. Pappo:**

1. Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Meeting: 2011 ASCO Annual Meeting
Presenter: Alberto S. Pappo, MD
Session: Pediatric Oncology I (Oral Abstract Session)

2. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study.

Meeting: 2010 ASCO Annual Meeting
Presenter: Alberto S. Pappo, MD
Session: Sarcoma (Oral Abstract Session)

3. The Study of Rare Tumors within the Context of a Cooperative Group: The COG experience 2002-2007
Meeting: 2009 ASCO Annual Meeting  
Chair: Alberto S. Pappo, MD  
Session: Rare Tumors in Childhood (Education Session)  
More...

» Educational Book Manuscripts by A. S. Pappo:

1. Rare Cancers in Children: When Adult Tumors Occur in Children  
Source: 2006 Educational Book  
Category: Pediatric Cancer  
More...